RecruitingNCT06337227

Potential Role of Sirtuins As Epigenetic Biomarkers of the Patient with Atherosclerosis or Calcific Aortic Stenosis

Potential Role of Sirtuins As Epigenetic Biomarkers for the Clinical Management of the Patient with Atherosclerosis or Calcific Aortic Stenosis

Sponsor

IRCCS SYNLAB SDN

Enrollment

3 participants

Start Date

Oct 19, 2023

Study Type

OBSERVATIONAL

Conditions

Atherosclerosis and Calcific Aortic Stenosis with and Without Diabetes

Summary

The project aims to shed light on the role of Sirtuins, enzymes belonging to the third class of histone deacetylases (class III) involved in epigenetic modifications (deacetylation), focusing mainly on Sirtuin 6 (SIRT6), as a regulator of atherosclerosis and severe aortic valve stenosis through molecular-based and epigenetic studies in human VSMC cells.

Eligibility

Min Age: 18 Years

Inclusion Criteria3

Patients with atherosclerosis or calcific aortic stenosis with and without diabetes older than 18 years of either sex;
Patients without atherosclerosis undergoing surgical procedure for endocarditis;
Patients who will have signed informed consent

Exclusion Criteria2

Patients for whom biological material cannot be recovered for study purposes;
Patients who refuse to participate in the study

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTlncRNA signature analyses

Specific validation experiments will be performed by Real-Time PCR (C-reactive protein), Western Blot, flow cytometry and microscopy

Locations(1)

Irccs Synlab Sdn

Naples, Italy

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06337227